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Abstract
Multiplexed single-cell RNA-seq analysis of multiple samples using pooling is a promising experimental design,
offering increased throughput while allowing to overcome batch variation. To reconstruct the sample identify of each
cell, genetic variants that segregate between the samples in the pool have been proposed as natural barcode for cell
demultiplexing. Existing demultiplexing strategies rely on availability of complete genotype data from the pooled
samples, which limits the applicability of such methods, in particular when genetic variation is not the primary object
of study. To address this, we here present Vireo, a computationally efficient Bayesian model to demultiplex single-cell
data from pooled experimental designs. Uniquely, our model can be applied in settings when only partial or no
genotype information is available. Using pools based on synthetic mixtures and results on real data, we demonstrate
the robustness of Vireo and illustrate the utility of multiplexed experimental designs for common expression analyses.
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Background
Single-cell RNA-seq (scRNA-seq) is a rapidly evolving
technology. Robust protocols and reduced costs have fos-
tered applications in biomedicine, for example to identify
biomarkers in disease [1, 2], or to characterize the cellular
response to treatment and other external stimuli [3, 4].
Across these use cases, multiplexed experimental
designs that combine multiple samples in a single experi-
ment have critical statistical advantages compared to the
serial analysis of samples in independent experimental
batches [5, 6]. In particular, pooled designs allow disen-
tangling true inter-individual variation from experimental
batch variation. Pooled designs whereby a large number of
cells from distinct samples are processed in a joint fash-
ion are facilitated by the availability of droplet sequencing
methods in particular, including Drop-seq [7] and the 10x
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Genomics Chromium platform [8], which can assay tens
of thousands of cells in a single run.
The aforementioned advantages have motivated a series
of barcoding strategies to demultiplex samples from
pooled experiments. In addition to simplified experimen-
tal logistics and reduced batch variation, pooled designs
can also facilitate the identification of doublet cells. Exist-
ing barcoding strategies include molecular labelling prior
to analysis [9–12] as well as exploiting natural genetic bar-
codes of germline variants that segregate between pooled
individuals [13]. While molecular barcoding is in princi-
ple applicable to any study design, genetic barcoding is
both elegant and can be seamlessly integrated in exist-
ing scRNA-seq workflows, without the need to introduce
additional processing steps.
Multiplexed designs with genetic barcoding are partic-
ularly applicable in biomedical research, where the anal-
ysis of larger cohorts of genetically distinct individuals
is particularly relevant [14]. However, current methods
for demultiplexing genetically barcoded pools, such as
Demuxlet [13], require genotype reference data for the
pooled samples. Using variant information extracted from
the scRNA-seq reads, each cell is then assigned to a sam-
ple in the pool based on its genetic distance to genotypic
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states in the genotype reference database. While there is
a growing interest in multi-sample analyses to study the
effect of genetic variation between individuals at single-
cell level, e.g., [15–17], the requirement to supply a geno-
type reference database is prohibitive for studies without a
genetic focus per se. Consequently, the potential of pooled
experimental designs is currently not realized.
To address this, we here present Vireo (Variational
Inference for Reconstructing Ensemble Origins), a prin-
cipled Bayesian method to demultiplex arbitrary pooled
designs that combine genetically distinct individuals.
Uniquely, Vireo models the genotypes of each individual
as latent variables, which are inferred from the observed
scRNA-seq reads. The model can also leverage partial
genotype information, e.g., when genotype data are avail-
able for a subset of individuals, and hence can be applied
to a wide range of experimental settings.
Results and discussion
Vireo jointly assigns each cell to one of K individuals and
estimates the genotypic state of these individuals at known
polymorphic loci. Specifically, the model takes a set of
common genetic variants as input (for example derived
from the 1000 Genomes Project [18]), which are geno-
typed in each cell based on the scRNA-seq read data.
Despite the typically low coverage of single-cell RNA-seq
experiments, this approach allows for genotyping on the
order of 100 expressed variants per cell (e.g., using 3’ 10×
Genomics data; approx. 50,000 reads per cell, Fig. 1 and
Methods). By aggregating information across cells, these
sparse genotype data are sufficient to reconstruct par-
tial genotypic state of the individuals in the pool, which
in turn allows for probabilistic demultiplexing whereby
each cell is assigned to one of these individuals (Fig. 1).
Vireo also accounts for the possibility of doublets (two
or more cells processed as a “single cell” in the assay), by
considering cells with variants that are most consistent
with a genotypic state formed by the combination of two
individuals. Finally, the model estimates the most likely
number of pooled individuals, a feature that is useful if
some of the pooled samples drop out for experimental
reasons, and the method can incorporate partial genotype
data that are available for a subset of the pooled samples.
Model validation using synthetic data
Initially, we considered synthetic data with a known truth
to validate our approach. We considered raw 3’ single-
cell RNA-seq data from the 10x Genomics platform (v2
kit) for 16 genetically distinct samples from the census of
immune cells project that are available from the Human
Cell Atlas (Methods) [19]. We then synthetically mixed 8
of these samples (1000 cells per sample and 4000UMIs per
cell on average), and simulated 8% of the cells as doublets,
which were included alongside the sampled singlet cells
(“singlets"; Methods). Initially, we evaluated Vireo’s ability
to estimate the number of input samples, by comparing
the marginal likelihood of multiple Vireo runs assum-
ing increasing numbers of samples in the pool, ranging
from six to twelve. Notably, models with at least the true
number of input samples (K = 8) were differentiated
from models with too low sample counts based on the
elbow plot of the variational lower bound (Fig. 2a). We
also observed that models that assume larger pool sizes
(K > 8) tended to yield sparse solutions, which means
that only the relevant subset of latent samples required to
explain the data were used, indicating that the model is
robust to choosing more samples than necessary during
inference (Additional file 1: Figure S1).
Fig. 1 Illustration of Vireo for demultiplexing multi-sample scRNA-seq studies without reference genotype data. a, b The inference is based on
genotyped common polymorphic variants in each cell, defined based on a standard reference of common human variants. b, c The resulting sparse
read count matrices of alternative and reference alleles (displayed as compound matrix for simplicity; NA in white denotes no observed reads) are
then decomposed into a matrix of estimated genotypes for each input sample and a probabilistic cell assignment matrix
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Fig. 2 Evaluation of Vireo using synthetic mixtures of up to 16 scRNA-seq datasets, including a comparison to models that require genotype data of
the pooled samples (Vireo-GT and Demuxlet). a–c Assessment of Vireo performance on one representative simulated dataset consisting of 8 pooled
samples with 1000 cells per sample, 8% doublet rate, and 4000 UMIs per cell on average. a Vireo model evidence (variational lower bound) when
varying the pool size assumed in the model. b Adjusted Rand index (ARI) between the most likely inferred and the true singlet assignment, when
varying the assignment confidence. The recommended cutoff (prob_max >0.9 for Vireo and Vireo-GT, and PRB.SNG1 >0.67 for Demuxlet) are
highlighted as dot. c Receiver operating characteristic (ROC) curve for detecting doublets, when varying the assignment confidence. The
recommended cutoff (prob_doublet >0.9 for Vireo and Vireo-GT, and 0.67 for Demuxlet) are highlighted with dots. d–i Systematic assessment of
Vireo and alternative methods on simulated data using a range of parameter choices, using five replicate runs. d–f Area under ARI for singlet
assignment considering alternative simulation settings, either varying the number of input samples d, the number of total cells in the dataset
(doublet rate varied proportional; 1.2 to 12%; Methods) e, as well as the number of UMIs per cell f. g-i Area under the ROC for doublet detection,
considering the same simulation parameters as in panels d–f. Parameters not varied in either of these experiments were set to their default values
(indicated by the star symbol). Small dots in each experiment denote the five replicate simulation experiments, and the big dot denotes the median
performance across replicates
Next, we evaluated the performance of Vireo for singlet
assignment and doublet detection, where for compari-
son we also considered alternative models that require
full genotype data of the pooled samples (Demuxlet [13]
and Vireo-GT, i.e., Vireo with full genotype data; Meth-
ods). By measuring the adjusted Rand index (ARI) of
the most likely assignment of singlet cells to samples
with regard to the true assignments, we found that Vireo
achieved markedly accurate results, yielding comparable
performance as Vireo-GT and Demuxlet (Fig. 2b). We
also varied the assignment confidence (Methods), finding
that all three methods achieve near-perfect assignments
of the full set of singletons (recall = 1). In the following,
we consider the area under the ARI-recall curve (AUC)
as a measure to systematically assess the performance of
singlet assignment across a wider range of settings.
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Similar to Demuxlet, Vireo can also be used to iden-
tify doublet cells, provided that the doublets are formed of
combinations of cells from two genetically distinct sam-
ples in the pool. Vireo without genotype achieves doublet
detection with an overall AUC = 0.978 (98.7% sensitivity
and 96.7% specificity at prob_doublet>0.9, Fig. 2c), which
is only marginally lower than the performance achieved
when using genotype data (Vireo-GT or Demuxlet, both
AUC ≈ 0.995). In practice, and in the experiments
reported below, we recommend prob_max >0.9 as the
threshold for the singlet assignment, and prob_doublet
>0.9 for the detection of doublets (see Methods).
Exploring a wider range of settings, we also evaluated
the model when varying the number of multiplexed sam-
ples (Fig. 2d, g), the number of cells assayed in each
experiment (Fig. 2e, h), and the number of UMIs per
cell (Fig. 2f, i). As expected, the cell-assignment accuracy
decreased with increasing numbers of samples in the pool,
but Vireo retained high accuracy for up to 12 multiplexed
samples (Fig. 2d, g). Beyond 12 samples, there is a risk
that the Vireo solution represents a local optimum of the
variational lower bound, omitting one or multiple samples
present in the pool (Fig. 2d). Using current experimen-
tal technologies, however, such high multiplexes are not
commonly considered, as the necessary cell counts are
associated with greatly increased doublet rates (e.g., on
the 10x Chromium platform). Conversely, the accuracy of
cell-assignment was consistently high across a large range
of cell counts per sample (Fig. 2e), where larger numbers
of cells tended to result in increased accuracy. Similarly,
increasing the sequencing coverage resulted in improved
accuracy for doublet detection (Fig. 2i), whereas accurate
singleton assignments were achieved even with extremely
low UMI counts per cell (Fig. 2f ).
Next, we assessed the utility of partial genotype data
for a subset of samples in the pool, which as expected
increased the model performance, particularly in settings
with low sequencing coverage (1200 UMIs per cell, Addi-
tional file 1: Figure S2). We also evaluated the robustness
of Vireo when applying the model to biased pools of
samples, i.e., settings in which some samples contribute
a smaller than expected fraction of cells. Vireo robustly
detected and aligned cells to samples with a relative fre-
quency as low as 10% (Additional file 1: Figure S3), while
retaining high accuracy for doublet detection. However,
rare samples that were represented by fewer than 100 cells
could be be missed in some settings.
Finally, we assessed the accuracy of the genotype recon-
struction of the pooled samples, finding that Vireo implic-
itly provides accurate genotype information for expressed
variants (10 or more UMIs) detected in the scRNA-seq
data (overall precision > 0.96, with heterozygous sites
of lowest precision = 0.91; Additional file 1: Figure S4).
Although such estimated genotypic states are intrinsically
not available genome-wide, these partial genotype profiles
can be used as a linking key to align the reconstructed
samples to other omics data or to combine demultiplexed
datasets across experiments (Methods).
Application to real pooled data
Next, we applied Vireo to two real datasets that have
previously been considered to benchmark demultiplex-
ing methods that require genotype information for all
samples [13].
First, we considered a set of three multiplexed experi-
ments (Fig. 3a-c; W1-W3, between 3639 and 6145 cells) of
peripheral blood mononuclear cells (PBMCs) from eight
lupus patients. We applied Vireo without using geno-
type information to all cells across these three batches
(Methods), thereby also creating an implicit link across all
the three experiments. The Vireo cell assignments were
markedly consistent with the assignments obtained when
using Demuxlet, which, however, relies crucially on geno-
type data for all samples (Fig. 3a). Similarly, we observed
overall concordant doublet cell assignments, although
there were larger differences than for singlet assignments
(Fig. 3b). We also applied Vireo separately to each of the
three datasets and used the inferred genotype state of the
samples to link the sample identity across experiments ret-
rospectively (Fig. 3c). This result demonstrates the utility
of the inferred genotype data for integrating demulti-
plexed samples across experiments, and shows how the
inferred genotypes can also be used to link demultiplexed
scRNA-seq samples to other (sequencing-based) assay
data available from the same samples (Methods).
As a second use case, we considered two experiments of
PBMCs from the same eight patients: one batch with IFN-
β stimulation and a matched control experiment without
stimulus. Cells were cultured for 6 h after pooling, which,
in contrast to the first dataset, resulted in an imbalanced
distribution of cells across samples (Fig. 3d). Despite this
distributional bias, Vireo again yielded demultiplexing
results that were markedly consistent with the results
obtained by methods that require a genotype reference
(Fig. 3d, e), and Vireo enabled aligning samples across
both experiments (Fig. 3f ).
Leveraging multiplexed designs for differential expression
analysis
Finally, we considered the demultiplexed dataset consist-
ing of stimulated and unstimulated cells (Fig. 3d–f) to
explore the utility of multi-sample designs for differential
gene expression analysis. Graph-based clustering (imple-
mented in Scanpy [20]) applied to the joint dataset con-
sisting of stimulated and unstimulated cells from all eight
samples (Fig. 4c) identified eight major clusters, which
could be annotated by common cell types (Fig. 4a-b; Addi-
tional file 1: Figure S5). Next, we tested for differential
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Fig. 3 Evaluation of Vireo on data frommultiplexed human PBMCs. a–c Results obtained on two datasets consisting of two pools of 4 samples each,
as well as a third dataset consisting of the union of all 8 samples. a Concordance of singlet assignment and doublet detection between Vireo
without genotype data and Demuxlet applied with complete genotype reference. Bars denote the number of cells assigned to each sample, either
considering cells that were consistently assigned by both Vireo and Demuxlet (blue), or assigned exclusively by Vireo (green) or Demuxlet (red). b
Concordance of doublet detection between Vireo and Demuxlet when varying the assignment threshold for each method. Note, p denotes the
threshold prob_doublet in Vireo (x-axis) and Demuxlet (y-axis) respectively, and n denotes the number of detected doublets. Assignment of cells in
a is based on the most probable sample assignment, considering all cells that were not detected as doublet. Cells with a doublet probability
(p_doublet > 0.9 in Vireo; > 2/3 in Demuxlet) were labelled as doublet cells and are considered in b. c Alignment of samples, when applying Vireo
separately to the three datasets considered in a. Values in the heatmap denote the fraction of concordant genotype states between pairs of
samples from both Vireo runs, considering variants with a read coverage of at least 10 UMIs per sample. d–f Results from a second experiment,
consisting of two datasets with the same 8 samples pooled in two different conditions: unstimulated and stimulated. Results shown correspond to
the panels in a–c
gene expression between the stimulated and unstimulated
condition within each cell type (using edgeR, considering
cells as replicates [21]). Considering B cells as a represen-
tative example (see Additional file 1: Figure S8–S11 for
full results), this analysis identified between 78 and 477
DE genes in individual samples (FDR<5%; Fig. 4f ), with
cell count being a major explanatory factor for differences
in the number of DE genes (Fig. 4c). Although globally,
DE genes tended to be recurrently detected in multiple
samples (Fig. 4e), there was a substantial fraction of DE
genes that were private to individual samples. For exam-
ple, the gene OAZ1 (Fig. 4d) was differentially expressed
in four of eight samples, highlighting the relevance of
inter-individual differences (more examples in Additional
file 1: Figure S6). We also explored carrying out joint test-
ing across all samples (using samples as an explanatory
factor in the model in edgeR; Methods), which led to
broadly similar conclusions (Additional file 1: Figure S7).
Conclusion
Here, we have presented Vireo, a Bayesian method for
demultiplexing pooled single-cell RNA-seq datasets by
exploiting natural genetic barcodes and cell genotyp-
ing based on scRNA-seq reads. Uniquely, Vireo does
not require any reference genotype data of the spe-
cific samples that are pooled in the experiment, while
achieving demultiplexing accuracies that are comparable
to methods that require a genotype reference. Vireo is
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Fig. 4 Case study of differential expression analysis of INF-β stimulated PBMCs using two matched pools that consist of 8 samples. a UMAP
representation of single-cell transcriptome profiles, colored by eight major cell types identified. Note, M denotes Monocytes. b Analogous UMAP
representation colored by the experimental condition: stimulated versus unstimulated. c The number of stimulated and unstimulated B cells
sequenced in each of the 8 samples. d–f Differential gene expression (DE) analysis between stimulated and unstimulated B cells. d The expression
level of an example gene OAZ1, depicting the distribution of expression levels in both conditions, either considering each sample separately (S1..S8)
or considering aggregated data pooled across all samples (All). FDR: adjusted P value (Benjamini-Hochberg) of each DE test between conditions
with likelihood-ratio test. CPM: count per million. e Number of recurrently detected DE genes between conditions (FDR< 0.05), detected in at least
one to eight samples. Box plots in gray show the recurrence expected by chance (based on 200 permutations). f The number of DE genes in each of
the 8 samples, categorized by the number of recurrent DE discoveries across samples, that is the number of individuals in which a given gene is
identified as DE (FDR< 0.05)
implemented using computationally efficient variational
Bayesian inference, which provides a fully Bayesian treat-
ment while retaining scalability to large datasets.
Using synthetic mixtures of cells, we have evaluated
the accuracy of Vireo for demultiplexing pooled sam-
ples, and found it robust to a variety of settings. We
also demonstrated the model’s flexibility for handling par-
tial genotype data for some of the samples, should these
data be available. Unsurprisingly, we observed that the
accuracy of the genotype estimation step per sample is
primarily linked to the sequencing coverage, which also
substantially affects the ability to detect doublet cells. As
the exact requirements for the optimal sequence cover-
age depend on the cell count and the number of pooled
samples, we provide a simulation framework that enables
the user to explore parameters thereby aiding the exper-
imental design of pooled studies. If cells from the same
individuals are assayed in multiple batches, Vireo can also
demultiplex them jointly, which boosts the assignment
accuracy, especially in experiments with lower read cover-
age. Furthermore, the estimated genotypes for individual
samples enable aligning samples from the scRNA-seq data
with other ’omics data for the same samples (Fig. 3c),
which provides a flexible approach for linking samples
across experiments, including multi-omics treatment-
control designs.
We noticed that the accuracy of demultiplexing with-
out a genotype reference starts to deteriorate for pools
with more than 12 samples. Increased sequencing cover-
age may allow for demultiplexing even larger pools, but
there remain general experimental limitations for such
designs. In particular, as long as the doublet rates scales
with increased cell count such designs remain of limited
interest.
As future technologies that motivate even larger pool
sizes become available, extensions of Vireo that can handle
such settings may be warranted. Notably, the demultiplex-
ing accuracy is also linked to read coverage per cell as well
as total cell count, two characteristic quantities that are
likely to improve as single-cell technologies continue to
mature.
As a reference-free method, Vireo is particularly useful
in settings where samples are treated as biological repli-
cates and the primary object is the variation between sam-
ples or groups, which does not require the explicit iden-
tification of individual samples in the pool (Fig. 3 and 4).
Beyond that, Vireo has the intrinsic limitation that the
inferred samples cannot be directly identified or linked
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to metadata. However, when the necessity for sample
identity arises, the estimated genotype states are read-
ily available for linking the samples to other ’omics data,
e.g., other scRNA-seq batches (Fig. 3c, f ) or bulk RNA-
seq (Additional file 1: Figure S12). These principles can
be applied to any read-based assay, which provides geno-
types. Finally, it is straightforward to generate targeted
qPCR-based genotypes for a minimal set of discrimina-
tory variants (Additional file 1: Figure S13). The Vireo
software provides helper functions for designing such
experiments, which directly leverages the reconstructed
genotypes in the pool to define a small set of discrimi-
natory variants (Methods). Vireo may also prove suitable
for demultiplexing pooled samples for other read-based
single-cell assays such as single-cell ATAC-seq, but further
benchmarking on appropriate datasets would be needed
and was not explored in this work.
Molecular barcoding strategies, e.g., [9–12], have
recently emerged as an alternatives to genetic barcod-
ing in many respects courtesy of their more universal
applicability. For example, molecular barcoding enables
pooling multiple treatment conditions or tissues from the
same individual or from individuals with the same genetic
background (e.g., inbred model organisms). Nevertheless,
natural genetic variants as barcode, which thanks to Vireo
now can be applied even when no genotype data are avail-
able, have the advantage of avoiding additional laboratory
work, thus reducing the logistical complexity, which can
impact cost, processing efficiency and data quality.
Methods
Vireo model
Given a list of N common variants, we extract allelic
expression of these variants in each of M cells with RNA-
seq data (see below for details on the read pileup approach
for variant genotyping). Let A and D respectively denote
the read or UMI count matrices for the alternative allele
(i.e., ALT) and the total read depth (i.e., sum of ALT and
REF) forN variants acrossM cells. Vireo models variation
in these counts matrices by employing a clustering model
with clusters corresponding to K individuals in the pool,
with (unknown) genotype states G. The values of G take
on values of 0, 1, or 2, corresponding to homozygous REF,
heterozygous and homozygous ALT alleles.
The observed alternative allele counts A are modelled as
binomial distributed given the read depths
p(ai,j|di,j, θt) = Binom(ai,j|di,j, θt), t ∈ T = {0, 1, 2},
(1)
where t is the true genotype of variant i in cell j, and θt is
the binomial rate parameter that encodes the correspond-
ing allele dosage of the alternative allele for genotype t.
Theoretically, the allele dosage is θt = t/2, whereas in
practice we allow for deviations to account for sequencing
errors, genotype estimation errors, and allelic imbalance.
The genotype in a given cell is defined by a clustering
model where the latent genotype t for variant i in cell j is
coded by two indicator variables: the cell assignment vec-
tor Zj, which assigns cell j to a latent sample in the pool,
and the genotype identity Gi,k , which defines the allelic
state of variant i in sample k. Specifically, the indicator
variable Zj,k = 1 if cell j is assigned to sample k and 0
otherwise; we also impose the constraint
∑
k Zj,k = 1,
which means that in expectation each cell originates from
exactly one sample. Analogously, the indicator variable
Gi,k,t = 1 if the genotype of variant i in sample k is t, and
0 otherwise, and we again require
∑
t Gi,k,t = 1. The cell
assignment matrix Z is strictly unknown and needs to be
estimated from the observed data. In general, the geno-
type matrix G is also unknown and is estimated jointly
withZ. If genotype information is available for one ormul-
tiple samples in the pool, this information can be encoded
as an informative prior on G; see below.
The likelihood of the full datasets, spanning all N vari-
ants that were genotyped in each of M cells given the cell
assignment matrix Z, the genotype matrixG and binomial
parameter θ follows as:
p(A,D|Z,G, θ) =
N∏
i=1
M∏
j=1
K∏
k=1
∏
t∈T
p(ai,j|di,j, θt)Zj,k×Gi,k,t
(2)
To complete the definition of the model, we introduce
prior distributions on the latent variables, which results
in the following joint distribution over both observed and
latent variables
p(A,D,Z,G, θ) = p(A,D|Z,G, θ)p(Z|π)p(G|U)p(θ |α,β)
(3)
For computational convenience, we use conjugate prior
distributions, namely a beta distribution for θ and multi-
nomial distributions for both Z and G.
p(Zj,k = 1|π) = Multinom(π) = πk
p(Gi,k,t = 1|U) = Multinom(ui,k) = ui,k,t
p(θt|α(0)t ,β(0)t ) = beta
(
θt|α(0)t ,β(0)t
) (4)
The hyper parameters are constant and set as follows. We
use an uninformative prior for Z: πk = 1/K , which cor-
responds to a uniform assignment probability of cells to
samples. The user can define other multinomial proba-
bilities, for example to encode known bias in the sample
representation. Similarly, we employ a uniform prior on
genotype G, i.e., ui,j,t = 1/3 if no genotype data are avail-
able. If the genotypes are partially known for a subset
of samples and/or variants, a corresponding informative
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prior is encoded. Specifically, ui,j,t takes the known geno-
type value with a relax rate ξ , i.e., ui,j,t = 1 − ξ if the
known genotype is t, otherwise ui,j,t = ξ . The error rate
parameter is set to ξ = 0.05 by default.
Finally, the hyper parameter for the beta prior on the
allelic rate θ is determined using known germline vari-
ants with high coverage: θ0 ∼ beta(0.3, 29.7), θ1 ∼
beta(3, 3), and θ2 ∼ beta(29.7, 0.3), with which the
posterior of θ will be obtained by fitting to the dataset.
Variational Bayesian inference
Analytical calculation of the posterior distribution of all
latent variables given the observed data p(Z,G, θ |A,D)
is not tractable. Thus, we consider variational Bayesian
inference [22] to obtain an approximate solution, thereby
retaining the benefits of a Bayesian treatment while
achieving computational scalability to larger scRNA-seq
datasets. Briefly, the objective of variational inference is to
approximate the exact (intractable) posterior distribution
of the latent variables p(Y|X) by a factorized distribution
q(Y) = ∏i qi(Yi), where Y denotes a set of latent variables
and X denotes the observed variables. The parameters of
the variational distribution q(Y) are determined with the
objective to minimize the Kullback-Leibler (KL) diver-
gence between the approximate distribution q(Y) and the
actual posterior distribution p(Y|X)
KL(q(Y)||p(Y|X)) =
∫
q(Y) log q(Y)p(Y|X)dY. (5)
This objective is equivalent to maximizing the lower
bound of the full distribution L(q), as the log marginal
probability of the observed variables is a constant, as
follows,
log(p(X)) = L(q) + KL (q(Y)||p(Y|X)) , (6)
where the lower bound L(q) is defined as follows,
L(q) =
∫
q(Y) log p(Y,X)q(Y) dY. (7)
A set of iterative update equations can be derived, which
are guaranteed to increase the lower bound
qj(Yj) = exp
{
Ei=j log (p(Y,X))
}
∫
exp
{
Ei=j log (p(Y,X)
}
dYj
. (8)
Here, Ei=j denotes an expectation with respect to the
distributions qi(Yi) for all i = j.
For inference in Vireo, we assume a fully factorized
distribution q(Z,G, θ) = q(Z)q(G)q(θ) to approximate
the true posterior distribution p(Z,G, θ |A,D), and we
assume that Z and G follow categorical distributions,
and θ follows beta distributions. Based on this assump-
tion, the lower bound can be computed as in Eq. 7 (See
Additional file 1: Supplementary Methods Equation (S1-
6)). Following Eq. 8, it is possible to derive iterative update
equations for the Q distribution of the latent variables
(see Additional file 1: Supplementary Methods Equation
(S7-12) for full details).
q∗(Z) =
M∏
j=1
K∏
k=1
rZj,kj,k ;
rj,k =
πk exp
∑N
i=1
∑
t∈T
{
g˜i,k,t[ ai,jϕ(α˜t) + bi,jϕ(β˜t)]
}
∑K
h=1 πh exp
∑N
i=1
∑
t∈T
{
g˜i,h,t[ ai,jϕ(α˜t) + bi,jϕ(β˜t)]
}
(9)
q∗(G) =
N∏
i=1
K∏
k=1
∏
t∈T
gGi,k,ti,k,t ;
gi,k,t =
ui,k,t exp
∑M
j=1
{
r˜j,k
[
ai,jϕ(α˜t) + bi,jϕ(β˜t)
]}
∑
h∈T ui,k,h exp
∑M
j=1
{
r˜j,k
[
ai,jϕ(α˜h) + bi,jϕ(β˜h)
]}
(10)
q∗(θ) =
∏
t∈T
beta(θt|αt ,βt);
αt = α(0)t +
N∑
i=1
M∑
j=1
K∑
k=1
r˜j,k g˜i,k,tai,j,
βt = β(0)t +
N∑
i=1
M∑
j=1
K∑
k=1
r˜j,k g˜i,k,tbi,j
(11)
Here, we introduce bi,j = di,j − ai,j to simplify the nota-
tion and ϕ(·) denotes the digamma function. To mitigate
potential local optima, multiple random restarts are con-
sidered (default: 50 restarts) and the solution that maxi-
mizes the variational lower bound is selected. Thanks to
our implementation with sparse matrix data structures
and the support of multiple threads, the Vireo model is
computationally efficient. On a laptop with 16 G memory
and two 3.5-GHz CPUs, Vireo finishes a two-run estima-
tion (see next section) in 6.7 min for 14,619 cells in an
eight sample pool and 58.1 s for 6145 cells in another eight
sample pool (results in Fig. 3).
Vireo with known genotype or partial genotype
Besides demultiplexing pooled scRNA-seq without any
genotype information, Vireo is also able to leverage any
available genotype information. In the case that the geno-
type is available for all pooled samples, we only use the
variants with known genotype and set the genotype prob-
ability variable G as known and fixed, which can be
derived from the GT tag (for categorical genotype), GP
or GL tag (genotype probability or likelihood) in the VCF
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file. By default, we use GT as it is the most commonly
available tag.
Alternatively, Vireo also supports the use of any partial
genotypes via a two-step run approach. In the first run,
Vireo does not use any genotype information but infers
the genotype for each sample. Then, we align the sam-
ples with known genotype to these identified samples in
this run and replace the estimated genotype probability
with the input known values. Therefore, we obtain a geno-
type probability matrix with mixed known and inferred
samples, which we then use as a prior of G, instead
of the default uniform prior in the second run. Finally,
we report the results of the second run as the result of
Vireo.
Estimation of the number of pooled samples
Access to the variational lower bound (Eq. 7) allows
for estimating the number of samples in a given
pool. Briefly, by comparing alternative Vireo runs with
increasing numbers of samples it is possible to iden-
tify the most probable value with the elbow plot (e.g.,
Fig. 2a), which provides an objective means to define this
parameter.
A second strategy is to set a large number of samples
and prune some of the samples post hoc, as the varia-
tional Bayes model is self-regularizing and hence avoids
over-fitting (see Additional file 1: Figure S1). In practice
this approach can also increase robustness as the effective
number of samples in a pool can be larger than anticipated
due to doublets; see Section below.
Multiple random initializations
When genotype is not given, Vireo uses a pre-step with
multiple random initializations to avoid local optima. By
default, Vireo runs for 50 random initializations, eachwith
a short iterations (15 by default). Then the initialization
with highest log likelihood will be continued.
As discussed in the above subsection, another strategy
to find all K pooled samples is searching from a larger
number of clusters. By default, we search K +√K clusters
in this pre-step, and only keep the K clusters with largest
number of assigned cells to continue, and discarded the√
K smaller clusters.
Doublet detection
To detect doublets, we construct the genotype of each
pair of samples and expand the K biological samples by
introducing in additional (K − 1) ∗ K/2 doublet com-
petitors. For simplicity, we assume that the genotype of a
doublet sample can be described as the average between
two combined samples. Specifically, for a given variant
and genotype, probability vectors for two samples are
x =[ x0, x1, x2] and y =[ y0, y1, y2], we define the expected
genotype for the doublet sample as follows,
p(t = 0) = x0y0
p(t = 1) = x1y1 + x0y2 + x2y0
p(t = 2) = x2y2
p(t = 0.5) = x0y1 + x1y0
p(t = 1.5) = x1y2 + x2y1
(12)
where we introduce two pseudo-genotypes t = 0.5 and
t = 1.5 respectively for combinations of genotype 0 &
1 and 1 & 2 in the doublet sample. For convenience, we
consider the binomial parameters for the alternative allelic
reads and assume that the binomial parameters θ0.5 and
θ1.5 also follow beta distributions. We approximate the
hyper-parameters of the beta distribution empirically by
respectively taking the ratio and shapes with the arith-
metic and geometric means from the two ordinary geno-
types. The resulting distribution of θ0.5 can be expressed
as follows
p(θ0.5) = beta(α0.5,β0.5)
α0.5
α0.5 + β0.5 =
1
2
(
α0
α0 + β0 +
α1
α1 + β1
)
(α0.5 + β0.5)2 = (α0 + β0) × (α1 + β1).
(13)
Similarly, we define the distribution of θ1.5.
In this augmented model, we have the full distribution
for the extended genotype reference G and θ , consist-
ing of K biological and (K − 1) ∗ K/2 doublet samples.
In this model we can calculate the probability that a cell
originates from one of the doublet samples using Eq. 9.
As an additional refinement, we specify a non-uniform
prior on η to define the a priori belief of observing a
doublet. Specifically, the prior binomial distribution π is
constructed as follows
p(πh) =
{
(1 − η)/K , 1 ≤ h ≤ K ; (singlet)
η/K2, K < h ≤ K + K2; (doublet)
(14)
where K2 = (K − 1) × K/2 as number of the com-
bined sample pairs. The prior probability for doublet cells
is low in most assays, e.g., η = 0.05. In case of the 10x
Chromium platform, the prior value can be estimated as
a function of the number of loaded cells M, e.g., η =
M/100, 000 following [13], which by default is used in our
experiments.
Therefore, we can obtain the posterior of each cell’s
sample identity, i.e., the probability of cell j coming from
any of the K input samples or K2 combined sample pairs
(i.e., doublet). We use the highest assignment probability
of the K input samples, prob_max, as the confidence score
for singlet assignment and use the summarized probability
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of all K2 sample pairs as the confidence score of a doublet,
namely prob_doublet.
Alignment of samples betweenmultiple data sets
Vireo implicitly estimates the genotypes for the subset of
variants with sufficient coverage (good accuracy for vari-
ants with >10 reads per sample; see Additional file 1:
Figure S4). Among other use cases, these estimated geno-
types allow for aligning scRNA-seq profiles from samples
in a pool to other ’omics data by matching genotype
profiles.
When Vireo is applied to multiple data sets that con-
sist of the same samples, the estimated genotype also
allows for aligning samples across data sets (e.g., Fig. 3c,
f for multiple pools, and Additional file 1: Figure S12 for
multiple ’omics). The software implementation of Vireo
provides support functions for this step by calculating the
fraction of variants with matched genotype between two
or multiple experiments.
Identification of discriminatory variants
Given a set of variants for which estimated genotypes
are available, the Vireo software implements a heuristic
to define a minimal and informative set of discrimina-
tory variants. This set of variants can be used to perform
qPCR-based genotyping or for other targeted genoytping
methods. Briefly, the algorithm implemented in Vireo pri-
oritizes variants with largest information gain in splitting
samples, as follows.
1 Remove variants with <20 UMIs per sample.
2 Initialize the variant set S = {}, and the split T among
K samples, and calculate the initial entropyH(T) = 0
3 Rank variants by the information gain
IG(T , v) = H(T) − H(T |v)
4 Select the variant with highest information gain and
update S, T, and H(T)
5 If H(T) = log2(K), return S and T, otherwise go to
step 3.
Additionally, variants with homozygous alternative alle-
les in the pooled samples can also be filtered out before
hand if needed. Examples of discriminatory variant sets
for the six-sample pool from HipSci project are shown in
Additional file 1: Figure S13.
Differential expression analysis
Differential expression analysis was performed with
edgeR [21] between stimulated and control samples (Fig. 4
and Additional file 1: Figure S7–S11). A generalized linear
model (negative binomial regression) is applied in edgeR
to test whether the stimulation contributes to the expres-
sion variation on a certain gene by using a likelihood-ratio
test. Using the raw UMI counts as input to edgeR, we
performed cell type specific DE analysis with the follow-
ing three different strategies for all cells jointly (Additional
file 1: Figure S7).
Method 1: y ∼ cdr+ condition+ sample, where y is the
expression count for a specific gene, which is regressed on
three covariates: cdr, the cell detection rate (i.e., the frac-
tion of expressed gene in each cell), stimulation condition
and the sample identity.
Methods 2 and 3: y ∼ cdr + condition, where we ignore
the sample identity of each cell in the pool (Method 2).
This same model can also be used in a pseudo-bulk man-
ner where we aggregate the counts for all cells of the
same type in a sample (Method 3). Alternatively, we can
always apply this model at single-cell level for each sample
separately (Fig. 4d-f ).
ScRNA-seq data from Demuxlet paper
In this study, we considered two existing multiplexed
scRNA-seq datasets that consist of a total of five batches
[13]. Raw .bam files were obtained from the Gene Expres-
sion Omnibus (GEO; accession number GSE96583).
The processed results from Demuxlet for these five
batches were directly downloaded from https://github.
com/yelabucsf/demuxlet_paper_code. Approximately 37
million common variants (allele frequency > 0.0005)
extracted from the 1000 Genome Project, phase 3 [18]
were used as candidate variants for scRNA-seq genotyp-
ing. We provide an companion Python package cellSNP
[23] for this task, which enables generating selected
pile-ups from scRNA-seq data. We discarded non-bi-
allelic variants as well as variants with fewer than 20
total UMIs across all cells or minor (i.e., second) allele
has less than 10% of total UMIs. The final outputs
of cellSNP are two variants-by-cells matrices, A and
D, for UMI counts of alternative allele and the total
counts respectively, which are used as input for the Vireo
model.
Bulk RNA-seq and scRNA-seq from HipSci project
In order to link the inferred samples to other ’omics data,
we used one scRNA-seq pool for iPSC differentiation in
the HipSci project (10x Genomics platform, experiment
44, day 0) with six samples: pipw, jejf, qehq, juuy, uilk,
and toco [15], and their corresponding bulk RNA-seq
data for each sample [24] (http://www.hipsci.org). Both
scRNA-seq and bulk RNA-seq data sets were downloaded
in .bam files and genotyped on 7.4 millions common bi-
allelic variants (minor allele frequency >5%) extracted
from the 1000 Genome Project with the cellSNP pack-
age. For single-cell data, we only keep variants with minor
allele frequency ≥ 0.1 and ≥ 20 UMIs. For each bulk
RNA-seq sample, we also only keep variants with minor
allele frequency ≥ 0.1 but require ≥ 100 read counts.
Then the genotypes of each bulk RNA-seq sample can be
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used to align to the samples that are demultiplexed from
scRNA-seq data.
Synthetic data
We obtained raw 3’ scRNA-seq data based on 10x
Genomics platform (v2 kit) for 16 genetically distinct sam-
ples from the Human Cell Atlas (Census of Immune Cells)
[19]. These data set are not pooled and each sample has
its own sequencing run. We only used data from the first
channel (each sample with around 100 million reads),
which is in the range of a standard 10x sequencing run.We
first mapped the raw fastq files to the human genome hg38
by CellRanger v2.1 provided by 10x Genomics (cellranger
count command line). Then we used cellSNP to geno-
type 7.4 million common variants (minor allele frequency
>5%) extracted from the 1000 Genome Project for these
16 samples in a pseudo-bulk manner. We only keep vari-
ants with: 1) >100 UMIs summarized across 16 samples,
2) >10% UMIs from the minor allele, and 3) <5 UMIs for
other alleles (i.e., not annotated reference and alternative
alleles). Therefore, we obtained the genotypes of 62,193
variants for these 16 samples, which are fed into Demuxlet
and Vireo-GT.
By only keeping cells with>500 genes and>1000 UMIs,
we had in total 66,410 cells across 16 samples, with each
sample having 2495 to 4909 cells. On average, there are
4000 UMIs per cell (median 2700 UMIs). In the syn-
thetic mixture, we pooled reads for a subset of cells from
each sample (in .bam format, aligned reads) and gener-
ated multiplexed scRNA-seq data (also in .bam format).
The script to generate these synthetic data is provided in
Vireo’s GitHub repository. Doublets were added into the
pooled data by adding proportional extra cells and com-
bining themwith another cells randomly. The doublet rate
is N/100, 000 where N is the total number of cells in the
pool.
By default, we pooled 1000 cells from each of 8 sam-
ples with doublet rate of 8%. This simulator also allows
setting different size of input samples, for example by
setting one sample with fewer cells ranging from 50 to
500 (Additional file 1: Figure S3). With the synthetic
data in .bam format, we can even further subsample
reads by using samtools with -s argument, e.g., 15–75%
in Fig. 3f.
All these simulations were randomly repeated for five
times to account for the variability in the simulation.
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